Phase II trial of bryostatin 1 in patients with relapsed low-grade non- Hodgkin's lymphoma and chronic lymphocytic leukemia

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 825-828

  Varterasian, Mary L ^a   Mohammad, Ramzi M ^a   Shurafa, Muhammad S ^b   Hulburd, Kim ^a   Pemberton, Pamela A ^a   Rodriguez, Dorothy H ^a   Spadoni, Virginia ^a   Eilender, David S ^a   Murgo, Anthony ^c   Wall, Nathan ^a   Dan, Maria ^a   Al Katib, Ayad M ^a,d  

^a WAYNE STATE UNIVERSITY   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRYOSTATIN 1; CD22 ANTIGEN; GLYCOPROTEIN P 15095; VINCRISTINE;

ADULT; AGED; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CELL DIFFERENTIATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HUMAN; MALE; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FATIGUE; FEASIBILITY STUDIES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LACTONES; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOMA, NON-HODGKIN; MACROLIDES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NERVOUS SYSTEM DISEASES; PAIN; REMISSION INDUCTION; TREATMENT OUTCOME; VINCRISTINE;

EID: 12944249449     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Pettit, G. R., Gao, F., Blumberg, P. M., Herald, C. L., Coll, J. C., Kamano, Y., Lewin, N. E., Schmidt, J. M., and Chapuis, J. C. Antineoplastic agents. 340. Isolation and structural elucidation of bryostatins 16-18. J. Nat. Prod. (Lloydia), 59(Suppl. 3): 286-289, 1996.
2. Kraft, A. S., Smith, J. B., and Berkow, R. L. Bryostatin, an activator of calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic HL-60 cells. Proc. Natl. Acad. Sci. USA, 83: 1334-1338, 1986.
3. Mohammad, R. M., Al-Katib, A., Pettit, G. R., and Sensenbrenner, L. L. Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents. Cancer Res., 54: 165-168, 1994.
4. Mohammad, R. M., Diwakaran, H., Maki, A., Emara, M. A., Pettit, G. R., Redman, B., and Al-Katib, A. Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leuk. Res., 19: 667-673, 1995.
5. Al-Katib, A. M., Smith, M. R., Kamanda, W. S., Pettit, G. R., Hamdan, M., Mohamed, A. N., Chelladurai, B., and Mohammad, R. M. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin. Cancer Res., 4: 1305-1314, 1998.
6. Maki, A., Diwakaran, H., Redman, B., Al-Asfar, S., Pettit, G. R., Mohammad, R. M., and Al-Katib, A. The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Anticancer Drugs, 6: 392-397, 1995.
7. Mohammad, R. M., Al-Katib, A., Pettit, G. R., and Sensenbrenner, L. L. Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines. Leuk. Res., 17: 1-8, 1993.
8. Al-Katib, A., Mohammad, R. M., Dan, M., Hussein, M. E., Akhtar, A., Pettit, G. R., and Sensenbrenner, L. L. Bryostatin 1 induced hairy cell features on chronic lymphocytic leukemia cells in vitro. Exp. Hematol., 21: 61-65, 1993.
9. Al-Katib, A., and Mohammad, R. M. Differentiation of human B-cell tumors: a preclinical model for differentiation therapy. In: F. A. Valenote, A. Nakeff, and M. Valdivieso (eds.), Basic and Clinical Applications of Flow Cytometry, pp. 179-199. Norwell, MA: Kluwer Academic Publishers, 1996.
10. Varterasian, M. L., Mohammad, R. M., Eilender, D. S., Hulburd, K., Rodriguez, D., Pemberton, P. A., Pluda, J., Dan, M. D., Pettit, G. R., Chen, B., and Al-Katib A. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J. Clin. Oncol., 16: 56-62, 1998.
11. Cheson, B. D., Bennett, J. M., Grever, M., Kay, N., Kearing, M. J., O'Brien, S., and Rai, K. R. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87: 4990-4997, 1996.
12. National Cancer Institute. Guidelines for reporting of adverse drug reactions. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute, 1988.
13. Al-Katib, A., Mohammad, R. M., Khan, K., Dan, M., Pettit, G., and Sensenbrenner, L. L. Bryostatin 1-induced modulation of the acute lymphoblastic leukemia cell line Reh. J. Immunother., 14: 33-42, 1993.
14. Propper, D. J., Macaulay, V., O'Byrne, K. J., Braybrooke, J. P., Wilner, S. M., Ganesan, T. S., Talbot, D. C., and Harris, A. L. A Phase II study of bryostatin 1 in metastatic malignant melanoma. Br. J. Cancer, 78: 1337-1341, 1998.
15. Mohammad, R. M., Katato, K., Almatchy, V. P., Wall, N., Liu, K. Z., Schultz, C. P., Mantsch, H. H., Varterasian, M., and Al-Katib, A. Sequential treatment of human chronic lymphocytic leukemia (CLL) with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies. Clin. Cancer Res., 4: 445-453, 1998.
16. Mohammad, R. M., Varterasian, M. L., Aimatchy, V. P., Hannoudi, G. N., Pettit, G. R., and Al-Katib, A. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristarin PE and bryostatin 1. Clin. Cancer Res., 4: 1337-1343, 1998.